EDSA (Edesa Biotech) Pre-Tax Income : $-6.11 Mil (TTM As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Edesa Biotech Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Edesa Biotech's pretax income for the three months ended in Dec. 2024 was $-1.62 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-6.11 Mil. Edesa Biotech's pretax margin was %.

During the past 13 years, Edesa Biotech's highest Pretax Margin was -369.70%. The lowest was -2376.42%. And the median was -1304.86%.

Edesa Biotech Pre-Tax Income Historical Data

The historical data trend for Edesa Biotech's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edesa Biotech Pre-Tax Income Chart

Edesa Biotech Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Pre-Tax Income

Get a 7-Day Free Trial

-6.36

-13.34

-17.55

-8.37

-6.17

Edesa Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial															-1.68	-1.86	-1.67	-0.96	-1.62

Competitive Comparison of Edesa Biotech's Pre-Tax Income

For the Biotechnology subindustry, Edesa Biotech's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edesa Biotech's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Edesa Biotech Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Edesa Biotech's Pretax Income for the fiscal year that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-6.316	+	-0.006	+	0	+	0.153	+	8.8817841970013E-16
	=	-6.17

Edesa Biotech's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.597	+	-0.021	+	0	+	0.002	+	-0.0010000000000001
	=	-1.62

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.11 Mil.

Edesa Biotech (NAS:EDSA) Pre-Tax Income Explanation

Edesa Biotech's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-1.617	/	0
	=	%

During the past 13 years, Edesa Biotech's highest Pretax Margin was -369.70%. The lowest was -2376.42%. And the median was -1304.86%.

Edesa Biotech Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Edesa Biotech's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Edesa Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (NAS:EDSA) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Spy Court, Markham, ON, CAN, L3R 5H6

Website

https://www.edesabiotech.com

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Executives

Pardeep Nijhawan	director, 10 percent owner, officer: Chief Executive Officer	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Stephen Lemieux	officer: Chief Financial Officer	100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6
Joan Chypyha	director	100 SPY COURT, MARKHAM A6 L3R 5H6
Patrick Marshall	director	100 SPY COURT, MARKHAM A6 L3R 5H6
Van Der Velden Peter	director, 10 percent owner	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Michael J Brooks	officer: President	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Frank R. Oakes	director, officer: President, CEO, & Director	C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041
Sean Arthur Macdonald	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lorin K Johnson	director	3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303
Pardeep Nijhawan Medicine Professional Corp	10 percent owner	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Paul William Pay	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Carlo Sistilli	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lumira Capital Investment Management Inc.	10 percent owner	141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Daniel E. Morse	director	C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041